These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 28714964)

  • 1. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
    Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
    Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
    Li Y; Song Q; Day BW
    Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
    Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
    PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma.
    Wei Y; Maximov V; Morrissy SA; Taylor MD; Pallas DC; Kenney AM
    Mol Cancer Res; 2019 Jan; 17(1):186-198. PubMed ID: 30224541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noncanonical activation of GLI signaling in SOX2
    Swiderska-Syn M; Mir-Pedrol J; Oles A; Schleuger O; Salvador AD; Greiner SM; Seward C; Yang F; Babcock BR; Shen C; Wynn DT; Sanchez-Mejias A; Gershon TR; Martin V; McCrea HJ; Lindsey KG; Krieg C; Rodriguez-Blanco J
    Sci Adv; 2022 Jul; 8(29):eabj9138. PubMed ID: 35857834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
    Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
    Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects.
    Kresbach C; Holst L; Schoof M; Leven T; Göbel C; Neyazi S; Tischendorf J; Loose C; Wrzeszcz A; Yorgan T; Rutkowski S; Schüller U
    Neuro Oncol; 2024 Apr; 26(4):609-622. PubMed ID: 37767814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
    Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
    Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A CK1α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma.
    Rodriguez-Blanco J; Li B; Long J; Shen C; Yang F; Orton D; Collins S; Kasahara N; Ayad NG; McCrea HJ; Roussel MF; Weiss WA; Capobianco AJ; Robbins DJ
    Clin Cancer Res; 2019 Feb; 25(4):1379-1388. PubMed ID: 30487124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SHH inhibitors for the treatment of medulloblastoma.
    Samkari A; White J; Packer R
    Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sox2 requirement in sonic hedgehog-associated medulloblastoma.
    Ahlfeld J; Favaro R; Pagella P; Kretzschmar HA; Nicolis S; Schüller U
    Cancer Res; 2013 Jun; 73(12):3796-807. PubMed ID: 23596255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma.
    Vanner RJ; Remke M; Gallo M; Selvadurai HJ; Coutinho F; Lee L; Kushida M; Head R; Morrissy S; Zhu X; Aviv T; Voisin V; Clarke ID; Li Y; Mungall AJ; Moore RA; Ma Y; Jones SJ; Marra MA; Malkin D; Northcott PA; Kool M; Pfister SM; Bader G; Hochedlinger K; Korshunov A; Taylor MD; Dirks PB
    Cancer Cell; 2014 Jul; 26(1):33-47. PubMed ID: 24954133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
    Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
    Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
    Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
    PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WIP1 enhances tumor formation in a sonic hedgehog-dependent model of medulloblastoma.
    Doucette TA; Yang Y; Pedone C; Kim JY; Dubuc A; Northcott PD; Taylor MD; Fults DW; Rao G
    Neurosurgery; 2012 Apr; 70(4):1003-10; discussion 1010. PubMed ID: 22037313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hedgehog pathway permissive conditions allow generation of immortal cell lines from granule cells derived from cancerous and non-cancerous cerebellum.
    Heil C
    Open Biol; 2019 Jan; 9(1):180145. PubMed ID: 30958113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.
    Robinson GW; Orr BA; Wu G; Gururangan S; Lin T; Qaddoumi I; Packer RJ; Goldman S; Prados MD; Desjardins A; Chintagumpala M; Takebe N; Kaste SC; Rusch M; Allen SJ; Onar-Thomas A; Stewart CF; Fouladi M; Boyett JM; Gilbertson RJ; Curran T; Ellison DW; Gajjar A
    J Clin Oncol; 2015 Aug; 33(24):2646-54. PubMed ID: 26169613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy.
    Ocasio JK; Babcock B; Malawsky D; Weir SJ; Loo L; Simon JM; Zylka MJ; Hwang D; Dismuke T; Sokolsky M; Rosen EP; Vibhakar R; Zhang J; Saulnier O; Vladoiu M; El-Hamamy I; Stein LD; Taylor MD; Smith KS; Northcott PA; Colaneri A; Wilhelmsen K; Gershon TR
    Nat Commun; 2019 Dec; 10(1):5829. PubMed ID: 31863004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neogenin1 is a Sonic Hedgehog target in medulloblastoma and is necessary for cell cycle progression.
    Milla LA; Arros A; Espinoza N; Remke M; Kool M; Taylor MD; Pfister SM; Wainwright BJ; Palma V
    Int J Cancer; 2014 Jan; 134(1):21-31. PubMed ID: 23775842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-Catenin-Gli1 interaction regulates proliferation and tumor growth in medulloblastoma.
    Zinke J; Schneider FT; Harter PN; Thom S; Ziegler N; Toftgård R; Plate KH; Liebner S
    Mol Cancer; 2015 Feb; 14(1):17. PubMed ID: 25645196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.